ライフサイエンスコーパス: parainfluenza

1 enza B, two respiratory syncytial virus, one parainfluenza).

2 ommon viral infections such as influenza and parainfluenza.

3 onse to a cluster of hospital-acquired human parainfluenza 3 virus (HPIV3) infections at a children's

4 gainst multiple domains of the paramyxovirus parainfluenza 5 (PIV5) pre- and postfusion F and HN.

5 Parainfluenza and coronaviruses were also more common am

6 ignificantly increased from 4.1 to 31.8% for parainfluenza and from 0.08 to 0.44% for influenza virus

7 -derived peptide sequence that inhibits both parainfluenza and Nipah viruses, to investigate the infl

8 Besides influenza A and RSV, influenza B, parainfluenza and norovirus may also contribute substant

9 for influenza, respiratory syncytial virus, parainfluenza, and adenovirus infection.

10 hat fuse at the cell surface, including HIV, parainfluenza, and henipaviruses.

11 95% confidence interval [CI], 1.02-4.69) and parainfluenza-ARI (AOR, 1.86; 95% CI, 1.15-3.01), when c

12 Influenza and parainfluenza ARIs appeared to facilitate pneumococcal a

13 ate an etiologic role, whereas detections of parainfluenza, coronaviruses, rhinovirus, and adenovirus

14 luenza B, respiratory syncytial virus (RSV), parainfluenza, enterovirus, rotavirus, norovirus, Campyl

15 Crystal structures of related parainfluenza F glycoproteins have revealed a large conf

16 quely broad spectrum antiviral activity of a parainfluenza F-derived peptide sequence that inhibits b

17 d, particularly in relation to influenza and parainfluenza infections of the respiratory tract.

18 ant paramyxoviruses, such as measles, mumps, parainfluenza, Nipah, and Hendra viruses, infect host ce

19 Lower-respiratory-tract infection with parainfluenza (odds ratio [OR], 17.9 [95% confidence int

20 flammation and respiratory death after mouse parainfluenza or human influenza virus infection.

21 ted to test for respiratory syncytial (RSV), parainfluenza (PIV) and influenza viruses.

22 ically important viruses, such as influenza, parainfluenza, respiratory syncytial virus (RSV) and Ebo

23 nd early viral exposure to 3 common viruses (parainfluenza, respiratory syncytial virus, and picornav

24 % rhinovirus/enterovirus and 30.7% influenza/parainfluenza/respiratory syncytial viruses).

25 all viruses and was strongest for influenza/parainfluenza/respiratory syncytial viruses.

26 itis virus, measles, mumps, metapneumovirus, parainfluenza, rotavirus, respiratory syncytial virus, a

27 Similarly, murine parainfluenza (Sendai) respiratory viral infection cause

28 ce for control of infection because of mouse parainfluenza (Sendai) virus and human enterovirus D68 (

29 For human parainfluenza type 3 (HPIV3), one bifunctional site on H

30 In this study the solution dynamics of human parainfluenza type 3 hemagglutinin-neuraminidase (HN) ha

31 ubjects into respiratory syncytial virus and parainfluenza type 3 vaccine trials when subjects were s

32 A recombinant chimeric bovine/human parainfluenza type 3 virus (rB/HPIV3) vector expressing

33 For human parainfluenza type 3, one bifunctional site on HN can ca

34 Neu5Ac2en derivatives that target the human parainfluenza type-1 hemagglutinin-neuraminidase protein

35 alic acid-based inhibitors that target human parainfluenza type-1 hemagglutinin-neuraminidase.

36 V-respiratory syncytial virus (RSV) or human parainfluenza virus (HPIV) coinfections had wheezing tha

37 The human parainfluenza virus (hPIV) hemagglutinin-neuraminidase (

38 presence of the second binding site on human parainfluenza virus (hPIV) type 1, 2, and 3 and Sendai v

39 es, Respiratory Syncytial Virus (RSV), Human Parainfluenza Virus (HPIV), and Human Metapneumovirus (h

40 RSV, human metapneumovirus (HMPV), and human parainfluenza virus (HPIV), that have been reported in r

41 (23), human herpesvirus (HHV)-6B (10), human parainfluenza virus (HPIV)-2 (3), HPIV-3 (1), and human

42 for RSV (n = 35), 2.6 x 10(6) copies/mL; for parainfluenza virus (n = 35), 4.9 x 10(7) copies/mL; for

43 rs mutations in the P/V gene from the canine parainfluenza virus (P/V-CPI(-)) is a potent inducer of

44 Parainfluenza virus (PIV) commonly infects patients foll

45 RSV F and related parainfluenza virus (PIV) F proteins are cleaved by furi

46 Parainfluenza virus (PIV) in humans is associated with b

47 Data on characteristics and outcomes of parainfluenza virus (PIV) infections in these patients a

48 Parainfluenza virus (PIV) is a cause of respiratory trac

49 Parainfluenza virus (PIV) is a leading cause of lower re

50 Parainfluenza virus (PIV) is a negative-sense single-str

51 s of virus transcription and replication for parainfluenza virus (PIV) type 2, PIV3, PIV5, and mumps

52 mens), followed by human rhinovirus (17.8%); parainfluenza virus (PIV) types 1-4 (7.5%); enterovirus

53 ith RSV and were given a boost with RSV or a parainfluenza virus (PIV) vector expressing RSV fusion p

54 sting for respiratory syncytial virus (RSV), parainfluenza virus (PIV), and influenza A and B, and by

55 yncytial virus (RSV), influenza virus (Flu), parainfluenza virus (PIV), human metapneumovirus (HMPV),

56 us (HRV), respiratory syncytial virus (RSV), parainfluenza virus (PIV), influenza virus (InfV), metap

57 (HN, residues 37 to 56) of the paramyxovirus parainfluenza virus (PIV5), a region of the HN stalk tha

58 naturally occurring SV5 variant Wake Forest parainfluenza virus (WF-PIV) activates the synthesis of

59 detects influenza A virus (Flu-A) and Flu-B, parainfluenza virus 1 (PIV-1), PIV-2, and PIV-3, and res

60 l virus (RSV), human metapneumovirus (HMPV), parainfluenza virus 1 to 3 (PIV1, PIV2, and PIV3), and a

61 za A H3, influenza A H1N1/2009, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainflue

62 dated on human immunodeficiency virus, human parainfluenza virus 1-4, human metapneumovirus, human co

63 hese are encoded by mumps virus (MuV), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5

64 Simian virus 5 (SV5) targets STAT1, human parainfluenza virus 2 targets STAT2, and mumps virus tar

65 N1/2009, influenza B, parainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainflue

66 ith respiratory syncytial virus (RSV), human parainfluenza virus 3 (HPIV-3), and influenza virus on t

67 Human parainfluenza virus 3 (HPIV3) and respiratory syncytial

68 We previously reported that a human parainfluenza virus 3 (HPIV3) F peptide effectively inhi

69 titatively influence fusion promotion, human parainfluenza virus 3 (HPIV3) variants with alterations

70 oviruses parainfluenza virus 5 (PIV5), human parainfluenza virus 3 (HPIV3), and respiratory syncytial

71 yxoviruses, such as Nipah virus (NiV), human parainfluenza virus 3 (HPIV3), measles virus (MeV), mump

72 Parainfluenza virus 3 (PIV-3) infection is highly restri

73 The majority of this decrease was in parainfluenza virus 3 (PIV3) (8.3% to 2.2%, P < .001).

74 The secreted human parainfluenza virus 3 F forms a trimer with distinct hea

75 However, we found that a human parainfluenza virus 3 F-peptide is more effective at inh

76 eaved ectodomain of the paramyxovirus, human parainfluenza virus 3 fusion (F) protein, a member of th

77 homologous HN protein, as well as NDV-human parainfluenza virus 3 HN chimeras.

78 ection but similar to that for influenza and parainfluenza virus 3 infection in all age groups.

79 mumps virus, Newcastle disease virus, human parainfluenza virus 3, and Nipah virus.

80 arainfluenza virus 1, parainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, rhinovirus

81 cell lines with Sendai virus (SeV) or human parainfluenza virus 3, two prototypic paramyxoviruses, c

82 the shape of the mRNA abundance gradient in parainfluenza virus 3, whereas a combination of this fac

83 dence similar to that of influenza virus and parainfluenza virus 3.

84 Putative viral pathogens included human parainfluenza virus 4 (aOR 9.3, P = .12), human bocaviru

85 rus [EV], 118; bocavirus, 8; coronavirus, 7; parainfluenza virus 4, 4; Mycoplasma pneumoniae, 1).

86 arainfluenza virus 2, parainfluenza virus 3, parainfluenza virus 4, rhinovirus/enterovirus, respirato

87 hat Cav-1 colocalizes with the paramyxovirus parainfluenza virus 5 (PIV-5) nucleocapsid (NP), matrix

88 Parainfluenza virus 5 (PIV5) activates and is neutralize

89 For the paramyxoviruses parainfluenza virus 5 (PIV5) and mumps virus, M-NP inter

90 Proline substitution in this region of HN of parainfluenza virus 5 (PIV5) and Newcastle disease virus

91 rmined the structure of the L-P complex from parainfluenza virus 5 (PIV5) at 4.3- angstrom resolution

92 In this work, we generated a recombinant parainfluenza virus 5 (PIV5) containing NP from H5N1 (A/

93 The paramyxovirus parainfluenza virus 5 (PIV5) enters cells by fusion of t

94 igh similarity to the structure of prefusion parainfluenza virus 5 (PIV5) F, with the main structural

95 Because only the prefusion structure of the parainfluenza virus 5 (PIV5) F-trimer is available, to s

96 MR spectroscopy, we show that the TMD of the parainfluenza virus 5 (PIV5) fusion protein adopts lipid

97 ucts were coexpressed with the nonhomologous parainfluenza virus 5 (PIV5) fusion protein, indicating

98 Parainfluenza virus 5 (PIV5) HN exists as a noncovalent

99 Parainfluenza virus 5 (PIV5) is a member of the Paramyxo

100 Parainfluenza virus 5 (PIV5) is a promising viral vector

101 Parainfluenza virus 5 (PIV5) is a prototypical paramyxov

102 Parainfluenza virus 5 (PIV5) is an appealing vector for

103 Parainfluenza virus 5 (PIV5) is an enveloped, single-str

104 The P protein of parainfluenza virus 5 (PIV5) is an essential cofactor of

105 Parainfluenza virus 5 (PIV5) is thought to contribute to

106 To investigate the role of NP protein in parainfluenza virus 5 (PIV5) particle formation, NP prot

107 ation of copyback DVGs readily occurs during parainfluenza virus 5 (PIV5) replication, but that their

108 In this work, we tested a recombinant parainfluenza virus 5 (PIV5) strain expressing the glyco

109 serendipitously identified a viral mRNA from parainfluenza virus 5 (PIV5) that activates IFN expressi

110 Preparations of parainfluenza virus 5 (PIV5) that are potent activators

111 quence variation of 16 different isolates of parainfluenza virus 5 (PIV5) that were isolated from a n

112 unable to be recognized by measles virus and parainfluenza virus 5 (PIV5) V proteins were tested in s

113 We tested the recombinant parainfluenza virus 5 (PIV5) vectors expressing RSV glyc

114 he threonine residue at position 286 of P of parainfluenza virus 5 (PIV5) was found phosphorylated.

115 The V proteins of measles virus (MV) and parainfluenza virus 5 (PIV5) were introduced into HFLC u

116 rotein (prefusion form) of the paramyxovirus parainfluenza virus 5 (PIV5) WR isolate was determined.

117 Parainfluenza virus 5 (PIV5), a paramyxovirus, is not kn

118 Similar results were also observed with parainfluenza virus 5 (PIV5), a paramyxovirus, when neut

119 Here we show that vaccination with parainfluenza virus 5 (PIV5), a promising live viral vec

120 Infection by parainfluenza virus 5 (PIV5), a prototypical member of t

121 Parainfluenza virus 5 (PIV5), a prototypical paramyxovir

122 The genome of parainfluenza virus 5 (PIV5), a prototypical paramyxovir

123 V), human parainfluenza virus 2 (hPIV2), and parainfluenza virus 5 (PIV5), all members of the genus R

124 During the replication of parainfluenza virus 5 (PIV5), copyback defective virus g

125 Parainfluenza virus 5 (PIV5), formerly known as simian v

126 y, papaverine also inhibited paramyxoviruses parainfluenza virus 5 (PIV5), human parainfluenza virus

127 that a porcine isolate of the paramyxovirus parainfluenza virus 5 (PIV5), known as SER, requires a l

128 The strain diversity of a rubulavirus, parainfluenza virus 5 (PIV5), was investigated by compar

129 Previously, we developed two parainfluenza virus 5 (PIV5)-based RSV vaccine candidate

130 We previously generated a parainfluenza virus 5 (PIV5)-vectored vaccine candidate

131 In this study, we evaluated two parainfluenza virus 5 (PIV5)-vectored vaccines expressin

132 Similar results were also observed with parainfluenza virus 5 (PIV5).

133 he FP of the F protein of the paramyxovirus, parainfluenza virus 5 (PIV5).

134 f the matrix (M) protein of a paramyxovirus, parainfluenza virus 5 (PIV5).

135 -3 as a binding partner for the M protein of parainfluenza virus 5 (PIV5).

136 NASEK was dispensable for viruses, including parainfluenza virus 5 and Coxsackie B virus, that enter

137 ructed chimeras containing the ectodomain of parainfluenza virus 5 F (PIV5 F) and either the MPER, th

138 Here we report the crystal structure of the parainfluenza virus 5 F protein in its prefusion conform

139 ess the functional role of the paramyxovirus parainfluenza virus 5 F protein TM domain, alanine scann

140 Here, a soluble form of parainfluenza virus 5 F was triggered to refold using te

141 , we show that the FP from the paramyxovirus parainfluenza virus 5 fusogenic protein, F, forms an N-t

142 ng globular head domain of the paramyxovirus parainfluenza virus 5 HN protein is entirely dispensable

143 usion activation, F activation involving the parainfluenza virus 5 HN stalk domain, and properties of

144 Knockdown of IFIT1 restored parainfluenza virus 5 infection in IFN-alpha-pretreated,

145 By modeling the crystal structure of parainfluenza virus 5 into the density, it is shown that

146 The paramyxovirus parainfluenza virus 5 mediates membrane merger through i

147 t robust maturation following infection with parainfluenza virus 5 or influenza virus.

148 this study, we show that vaccination with a parainfluenza virus 5 recombinant vaccine candidate expr

149 ed "stalk exposure model" first proposed for parainfluenza virus 5 to other paramyxoviruses and propo

150 athogens: human respiratory syncytial virus, parainfluenza virus 5, and Sendai virus.

151 A parainfluenza virus 5-vectored vaccine expressing the na

152 1 (IFIT1) is the principal antiviral ISG for parainfluenza virus 5.

153 sequence, FPIV, important for the budding of parainfluenza virus 5.

154 recently published prefusogenic structure of parainfluenza virus 5/SV5 F places CBF(2) in direct cont

155 or detecting respiratory viruses, especially parainfluenza virus and adenovirus.

156 d five in which the PLx-RVP failed to detect parainfluenza virus and one in which the detection of in

157 ow fever virus, Japanese encephalitis virus, parainfluenza virus and Sendai virus.

158 2 unit, with respiratory syncytial virus and parainfluenza virus being the most common viruses isolat

159 sociation with age; especially rhinovirus or parainfluenza virus detection showed positive associatio

160 Parainfluenza virus epidemics were found mostly in sprin

161 By comparison, parainfluenza virus had longer duration of epidemics (6.

162 Analysis of parainfluenza virus infection in mice revealed an unexpe

163 We used mouse models of influenza and parainfluenza virus infection to show that intranasally

164 ccine nor clinically effective treatment for parainfluenza virus infection.

165 uenza virus, respiratory syncytial virus, or parainfluenza virus infection.

166 in mixed bone marrow chimeric mice during a parainfluenza virus infection.

167 Parainfluenza virus infections did not differentially af

168 to pneumonitis and/or mortality of treating parainfluenza virus infections with available (ribavirin

169 ools elicited by nonpersistent influenza and parainfluenza virus infections.

170 mouse model in which infection with a mouse parainfluenza virus known as Sendai virus (SeV) leads to

171 Early childhood infection with parainfluenza virus or respiratory syncytial virus is st

172 significance of membrane fusion activity in parainfluenza virus replication and pathogenesis in vivo

173 e (HN) glycoprotein plays a critical role in parainfluenza virus replication.

174 The parainfluenza virus simian virus 5 (SV5) is a poor induc

175 Human epithelial cells infected with the parainfluenza virus simian virus 5 (SV5) show minimal ac

176 SER virus is a type 5 parainfluenza virus that does not exhibit syncytium form

177 eviously described heterotypic peptides from parainfluenza virus that potently inhibit Nipah virus in

178 e protein or whole virus digests enables the parainfluenza virus to be identified and typed and for i

179 ontact transmission, the predominant mode of parainfluenza virus transmission, was modeled accurately

180 n to the catalytic binding site, HN of human parainfluenza virus type 1 (hPIV-1) may have a second re

181 Human parainfluenza virus type 1 (HPIV1) also causes severe pe

182 Sendai virus (SeV) and human parainfluenza virus type 1 (hPIV1) are highly similar in

183 We evaluated a version of human parainfluenza virus type 1 (HPIV1) bearing a stabilized

184 Human parainfluenza virus type 1 (HPIV1) is a significant caus

185 Human parainfluenza virus type 1 (HPIV1) is an important respi

186 Human parainfluenza virus type 1 (HPIV1) is an important respi

187 respiratory syncytial virus (RSV) and human parainfluenza virus type 1 (HPIV1) to HPIV4 infect virtu

188 onkeys from challenge with the related human parainfluenza virus type 1 (hPIV1), and SV has advanced

189 valuation of an attenuated recombinant human parainfluenza virus type 1 (rHPIV1) expressing the membr

190 Live attenuated recombinant human parainfluenza virus type 1 (rHPIV1) was investigated as

191 Recombinant human parainfluenza virus type 1 (rHPIV1) was modified to crea

192 Human parainfluenza virus type 1 is the major cause of croup i

193 Human parainfluenza virus type 2 (HPIV-2), an important pediat

194 e-defective BC-PIV vector derived from human parainfluenza virus type 2 (hPIV2) by a reverse genetics

195 lication during infection of A549 cells with parainfluenza virus type 2 (PIV2), PIV3, PIV5, or mumps

196 t for association with V proteins from human parainfluenza virus type 2, parainfluenza virus type 5,

197 metapneumovirus (44%), rhinovirus (34%), and parainfluenza virus type 3 (28%); respiratory syncytial

198 domains with their counterparts from bovine parainfluenza virus type 3 (BPIV3) F protein to direct i

199 doses of an intranasal vaccine using bovine parainfluenza virus type 3 (bPIV3).

200 ur previous observation on the role of human parainfluenza virus type 3 (HPIV 3) C protein in the tra

201 Paramyxovirus vaccine vectors based on human parainfluenza virus type 3 (HPIV-3) and Newcastle diseas

202 Human parainfluenza virus type 3 (hPIV-3) is a clinically sign

203 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major pediatric r

204 respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are major viral agent

205 SV), human metapneumovirus (hMPV), and human parainfluenza virus type 3 (hPIV3) are responsible for t

206 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are the first and sec

207 Respiratory syncytial virus (RSV) and human parainfluenza virus type 3 (HPIV3) are two major causes

208 The genomic promoter of human parainfluenza virus type 3 (HPIV3) contains multiple cis

209 genes, of a gene cassette encoding the human parainfluenza virus type 3 (HPIV3) hemagglutinin-neurami

210 plementation to follow the dynamics of human parainfluenza virus type 3 (HPIV3) HN/F pairs in living

211 We demonstrate that human parainfluenza virus type 3 (HPIV3) induces incomplete au

212 onnected to the stalk region of either human parainfluenza virus type 3 (HPIV3) or Nipah virus recept

213 against Ebola virus (EV), recombinant human parainfluenza virus type 3 (HPIV3) was modified to expre

214 rt here that for three paramyxoviruses-human parainfluenza virus type 3 (HPIV3), a major cause of low

215 Human parainfluenza virus type 3 (HPIV3), a paramyxovirus, is

216 common pediatric respiratory pathogen, human parainfluenza virus type 3 (HPIV3), as a vaccine vector

217 encephalomyocarditis virus (EMCV) and human parainfluenza virus type 3 (HPIV3), induced down-regulat

218 ing the childhood respiratory pathogen human parainfluenza virus type 3 (HPIV3), possess an envelope

219 For human parainfluenza virus type 3 (HPIV3), the effects of speci

220 For human parainfluenza virus type 3 (HPIV3), the receptor binding

221 aminidase (HN) surface glycoprotein of human parainfluenza virus type 3 (HPIV3).

222 Parainfluenza virus type 3 (PIV3) infections are a major

223 Parainfluenza virus type 3 (PIV3) is major pathogen of c

224 r the ability to inhibit the growth of human parainfluenza virus type 3 (PIV3), a nonsegmented negati

225 or with a chimeric recombinant bovine/human parainfluenza virus type 3 (rB/HPIV3) vector expressing

226 we used an attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) vector to express

227 We used a chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) vector to express

228 A live attenuated chimeric bovine/human parainfluenza virus type 3 (rB/HPIV3) was developed prev

229 s virus of the Arenaviridae family and human parainfluenza virus type 3 of the Paramyxoviridae family

230 yncytial virus, human metapneumovirus, human parainfluenza virus type 3, and measles virus, and highl

231 uses, including the childhood pathogen human parainfluenza virus type 3, enter host cells by fusion o

232 explores the binding and entry into cells of parainfluenza virus type 3, focusing on how the receptor

233 minidase abolished infection of HAE by human parainfluenza virus type 3, this treatment did not signi

234 vaccine for respiratory syncytial virus and parainfluenza virus type 3, two major causes of severe r

235 viruses, including the human pathogen human parainfluenza virus type 3, yet these compounds by thems

236 protective efficacy of an aerosolized human parainfluenza virus type 3-vectored vaccine that express

237 ses to administration of a cocktail of human parainfluenza virus type 3-vectored vaccines against ind

238 Human parainfluenza virus type 3-vectored vaccines offer benef

239 lymphocytic choriomeningitis virus and human parainfluenza virus type 3.

240 ction of interferon (IFN) alpha/beta against parainfluenza virus type 5 (PIV5), selectively inhibitin

241 teins from human parainfluenza virus type 2, parainfluenza virus type 5, measles virus, mumps virus,

242 Paramyxoviruses such as human parainfluenza virus type-3 (HPIV3) and measles virus (Me

243 We investigated the binding of human parainfluenza virus types 1 and 3 (hPIV1 and hPIV3, resp

244 luding influenza virus A, influenza virus B, parainfluenza virus types 1 and 3, respiratory syncytial

245 virus (RSV), influenza virus type A (FluA), parainfluenza virus types 1, 2, and 3 (PIV1, PIV2, and P

246 iratory syncytial viruses A and B; and human parainfluenza virus types 1, 2, and 3.

247 3, B, respiratory syncytial virus, and human parainfluenza virus types 1-2 and 3), and develop a meth

248 iruses, including influenza A and B viruses, parainfluenza virus types 1-3, respiratory syncytial vir

249 act of respiratory syncytial virus (RSV) and parainfluenza virus URIs on the frequency of AOM caused

250 ple viruses (respiratory syncytial virus and parainfluenza virus) and multiple phenotypes.

251 pproach is further demonstrated here for the parainfluenza virus, a virus which can be life threateni

252 or respiratory syncytial virus, 83 sites for parainfluenza virus, and 65 sites for metapneumovirus.

253 tory syncytial virus, human metapneumovirus, parainfluenza virus, and influenza virus) by reverse-tra

254 nfluenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus are the most co

255 nfluenza virus, respiratory syncytial virus, parainfluenza virus, and metapneumovirus.

256 ents with respiratory syncytial virus (RSV), parainfluenza virus, influenza virus, metapneumovirus (M

257 nfluenza virus, respiratory syncytial virus, parainfluenza virus, or metapneumovirus, or a combinatio

258 roviruses, influenza virus, metapneumovirus, parainfluenza virus, rhinovirus, and respiratory syncyti

259 ediates the cellular entry of influenza, the parainfluenza virus, some enteroviruses and the bacteriu

260 so showed that extraction will be needed for parainfluenza virus, which was only identified correctly

261 Similarly, F-glycoprotein trimers from human parainfluenza virus-type 3 and spike-glycoprotein trimer

262 rus, rhinovirus, and influenza virus but not parainfluenza virus.

263 t for lower-respiratory-tract infection with parainfluenza virus; it stabilized during the months aft

264 he hemagglutinin-neuraminidase (HN) of human parainfluenza viruses (hPIV) in vitro and protected mice

265 Human parainfluenza viruses (HPIVs) are a common cause of acut

266 Human parainfluenza viruses (HPIVs) are among the most common

267 glutinin-neuraminidase (HN) protein of human parainfluenza viruses (hPIVs) both binds (H) and cleaves

268 Human parainfluenza viruses (HPIVs) cause widespread respirato

269 The first step in infection by human parainfluenza viruses (HPIVs) is binding to the surface

270 The paramyxoviruses, including human parainfluenza viruses (HPIVs), cause a large share of th

271 Parainfluenza viruses (PIVs) are one of the most common

272 ed negative for respiratory syncytial virus, parainfluenza viruses (types 1-3), influenza A and B vir

273 FilmArray RP detected more parainfluenza viruses 1 and 3 than ProParaflu+ (18 versu

274 virus, influenza A virus, influenza B virus, parainfluenza viruses 1 to 3, and respiratory syncytial

275 nfluenza A virus H1-2009, influenza B virus, parainfluenza viruses 1 to 4, respiratory syncytial viru

276 syncytial virus; influenza A and B viruses; parainfluenza viruses 1, 2, 3, and 4; human metapneumovi

277 adenovirus, influenza A and B viruses, human parainfluenza viruses 1-3 (HPIV), respiratory syncytial

278 picornaviruses, coronaviruses 229E and OC43, parainfluenza viruses 1-3, influenza viruses AH1, AH3, a

279 in reaction for respiratory syncytial virus, parainfluenza viruses 1-4, influenza A and B, human meta

280 lture (metapneumovirus, coronaviruses [CoV], parainfluenza viruses 4a and 4b, and rhinoviruses) and t

281 nimal pathogens, such as measles, mumps, and parainfluenza viruses and the deadly henipaviruses Nipah

282 Parainfluenza viruses are a common cause of seasonal res

283 Parainfluenza viruses are known to inhibit type I interf

284 protein and nucleocapsid sustain assembly of parainfluenza viruses at the plasma membrane.

285 Three human parainfluenza viruses bind to glycans terminating with N

286 (RSV), adenoviruses, influenza viruses, and parainfluenza viruses by use of nested polymerase chain

287 Human parainfluenza viruses cause several serious respiratory

288 Parainfluenza viruses enter host cells by fusing the vir

289 Parainfluenza viruses initiate infection by binding to c

290 Paramyxoviruses such as human parainfluenza viruses that bear inserts encoding protect

291 ew evidence regarding strategies employed by parainfluenza viruses to effectively circumvent respirat

292 etapneumovirus, respiratory syncytial virus, parainfluenza viruses, and Haemophilus influenzae being

293 ly enriched rhinovirus, influenza virus, and parainfluenza viruses, and maintained the stoichiometric

294 causes of lower respiratory disease like the parainfluenza viruses, as well as agents of lethal encep

295 , which include respiratory syncytial virus, parainfluenza viruses, coronavirus, rhinovirus, and huma

296 ruses, including measles virus, mumps virus, parainfluenza viruses, respiratory syncytial virus, huma

297 tein subunits play the cell entry concert of parainfluenza viruses.

298 p of viruses that includes measles virus and parainfluenza viruses.

299 an respiratory syncytial virus and the human parainfluenza viruses.

300 y in all studied age groups; influenza B and parainfluenza were additionally associated in those aged